Article
Oncology
Alia M. Attia, Hanan A. Eltybe, Mayada F. Sedik, Ahmed Mubarak Hefni, Marwa Abdelgawad, Ashraf Farrag, Abdelhakeem A. Essa, Mohamed M. El-Barody, Noha M. Attia
Summary: This study aimed to compare the survival and toxicity profile between adjuvant temozolomide (TMZ) treatment for greater than six cycles and six cycles in patients with newly diagnosed glioblastoma multiforme (GBM) in Upper Egypt. The results showed that extended TMZ therapy did not significantly improve progression-free survival (PFS) or overall survival (OS) compared to the standard six-cycle course.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Yu Wang, Jianmin Zhang, Wenbin Li, Taipeng Jiang, Songtao Qi, Zhongping Chen, Jingbo Kang, Lei Huo, Yunjie Wang, Qichuan Zhuge, Guodong Gao, Yuping Wu, Hua Feng, Gang Zhao, Xiaopeng Yang, Hui Zhao, Yirong Wang, Hui Yang, Dezhi Kang, Jun Su, Liang Li, Chuanlu Jiang, Gang Li, Yongming Qiu, Weimin Wang, Handong Wang, Zaihua Xu, Liwei Zhang, Renzhi Wang
Summary: The study revealed that only 15.8% of Chinese GBM patients received treatments compliant with the Stupp regimen, with main deviations related to temozolomide dosages and treatment durations. Patients who received Stupp regimen-compliant treatments had longer overall survival and progression-free survival.
Article
Pharmacology & Pharmacy
Jigang Chen, Xin Tong, Mingyang Han, Songfeng Zhao, Linjin Ji, Yongkai Qin, Zilong He, Yuesong Pan, Chunhui Wang, Aihua Liu
Summary: The study found that RT plus TMZ treatment for elderly GBM patients in the US is associated with higher costs, but offers greater long-term survival and quality of life benefits. However, in China, this treatment strategy is not cost-effective and requires a decrease in the price of TMZ.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Loig Vaugier, Loic Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sebastien Frenel, Carole Gourmelon, Marie Robert, Stephane-Andre Martin, Tanguy Riem, Vincent Roualdes, Loic Campion, Augustin Mervoyer
Summary: The study reviewed elderly patients with GBM referred for 6-week CRT, finding that CRT treatment was feasible for this population, even in the case of post-operative neurological disabilities. Age and neurological disabilities did not necessarily affect patient outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa
Summary: This study evaluated the efficacy and safety of bevacizumab in Japanese patients with newly diagnosed glioblastoma and identified an expression classifier that may predict patient prognosis.
Article
Oncology
Lei She, Xuan Gong, Lin Su, Chao Liu
Summary: The combination therapy of nimotuzumab with radiation therapy and temozolomide shows potential efficacy in newly diagnosed EGFR-positive GBM patients, particularly those with unmethylated MGMT promoter.
Review
Multidisciplinary Sciences
Suely Maymone de Melo, Gustavo Nader Marta, Carolina de Oliveira Cruz Latorraca, Camila Bertini Martins, Orestis Efthimiou, Rachel Riera
Summary: This review found no evidence of a difference between the evaluated HRTs for efficacy and safety.
Article
Oncology
Maciej Harat, Maciej Blok, Izabela Miechowicz, Izabela Wiatrowska, Karolina Makarewicz, Bogdan Malkowski
Summary: This study evaluated the safety and efficacy of simultaneous integrated boost (SIB) planned using dual FET-PET for postoperative GBM treatment. The results showed that SIB with dual FET-PET improved survival outcomes, but there was a risk of radiation necrosis.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Summary: The efficacy of Bavituximab, a monoclonal antibody with anti-angiogenic and immunomodulatory properties, was evaluated in newly diagnosed patients with glioblastoma (GBM) who also received radiotherapy and temozolomide. The study showed that Bavituximab has activity in the treatment of newly diagnosed GBM and resulted in on-target depletion of intratumoral immunosuppressive MDSCs. Elevated pre-treatment expression of myeloid-related transcripts in GBM may predict response to Bavituximab.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, Roger Stupp, Burt Nabors, Olivier Chinot, Wolfgang Wick, Matthias Preusser, Thierry Gorlia, Michael Weller
Summary: Myelosuppression during temozolomide chemoradiotherapy is associated with the survival of patients with newly diagnosed glioblastoma. Female patients experience more marrow toxicity than males. Lymphopenia is related to the overall survival of patients.
Review
Oncology
Carlen A. Yuen, Marissa Barbaro, Aya Haggiagi
Summary: Management of elderly patients with newly diagnosed glioblastoma (eGBM) presents unique challenges. Although progress has been made in defining the optimal therapeutic approach for these patients, many questions remain unanswered.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Oncology
Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah
Summary: In newly diagnosed glioblastoma, continuing adjuvant TMZ beyond six cycles did not show an increase in either progression-free survival or overall survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
Summary: Treatment with chloroquine in combination with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma showed favorable toxicity and promising overall survival. The maximum tolerated dose was determined to be 200 mg of chloroquine daily. Further clinical studies are supported by these results.
Article
Oncology
Jie Chen, Tingting Wang, Wanming Liu, Hui Qiu, Nie Zhang, Xueting Chen, Xin Ding, Longzhen Zhang
Summary: This study suggests that extended adjuvant temozolomide treatment can significantly improve the prognosis of newly diagnosed glioblastoma patients, regardless of p53 mutation status. The effect of this treatment also varies among patients with different MGMT methylation, IDH1 mutation, and Ki67 expression levels.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
M. Janaki Ramaiah, K. Rohil Kumar
Summary: Glioblastoma multiforme (GBM) is an aggressive brain cancer with a short survival period, where mTOR and EGFR mediated signaling pathways play a crucial role in tumor aggressiveness and chemoresistance. Recent studies show that microRNAs can regulate these pathways, affecting cell sensitivity to chemotherapy.
MOLECULAR BIOLOGY REPORTS
(2021)
Article
Oncology
Manmeet S. Ahluwalia, David A. Reardon, Ajay P. Abad, William T. Curry, Eric T. Wong, Sheila A. Figel, Laszlo L. Mechtler, David M. Peereboom, Alan D. Hutson, Henry G. Withers, Song Liu, Ahmed N. Belal, Jingxin Qiu, Kathleen M. Mogensen, Sanam S. Dharma, Andrew Dhawan, Meaghan T. Birkemeier, Danielle M. Casucci, Michael J. Ciesielski, Robert A. Fenstermaker
Summary: SurVaxM is a peptide vaccine that activates the immune system against glioblastoma cells. The combination of SurVaxM and adjuvant chemotherapy can extend the progression-free survival of newly diagnosed glioblastoma patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Atulya Aman Khosla, Shreya Saxena, Ahmad Ozair, Vyshak Alva Venur, David M. Peereboom, Manmeet S. Ahluwalia
Summary: Neoplastic meningitis is a common complication of cancer with a poor prognosis. Current treatments aim to alleviate symptoms and preserve quality of life through a multimodal approach, including surgery, chemotherapy, and radiotherapy. Individualized treatment is based on guidelines and expert opinion. Novel therapies, such as targeted and immunotherapies, are being investigated in clinical trials. This article provides an updated review of treatment approaches in neoplastic meningitis.
Article
Oncology
Andrew Dhawan, Venkata S. K. Manem, Gabrielle Yeaney, Justin D. Lathia, Manmeet S. Ahluwalia
Summary: We compared gene expression in primary and recurrent glioblastoma samples, focusing on those with EGFR amplification. Our results show that EGFR-amplified tumors have altered gene expression in the EGFR pathway, but this difference is lost in recurrent disease. EGFR pathway overexpression may be a common mechanism underlying glioblastoma recurrence.
Editorial Material
Oncology
Rupesh Kotecha, Yazmin Odia, Atulya A. Khosla, Manmeet S. Ahluwalia
Summary: Glioblastoma is a common and aggressive primary brain tumor with a poor prognosis. The current standard treatment involves surgery, chemoradiotherapy, and maintenance chemotherapy. Clinical trials are being conducted to improve treatment outcomes. Recent research focuses on radiotherapy dose intensification, regulation of the tumor microenvironment, and exploration of immunotherapeutic approaches. This review article summarizes the current evidence-based management principles and discusses recent clinical trial data and ongoing studies.
JCO ONCOLOGY PRACTICE
(2023)
Article
Urology & Nephrology
Ahmad Ozair, Abhishek Kumar, Nishanth R. Subash, Sahaam Mirza, Atulya A. Khosla, Manmeet Ahluwalia, Philipp Dahm
Article
Oncology
Douglas B. Johnson, Michael B. Atkins, Cassandra Hennessy, Trisha Wise-Draper, Hannah Heilman, Joy Awosika, Ziad Bakouny, Chris Labaki, Renee Maria Saliby, Clara Hwang, Sunny R. K. Singh, Nino Balanchivadze, Christopher R. Friese, Leslie A. Fecher, James J. Yoon, Brandon Hayes-Lattin, Mehmet A. Bilen, Cecilia A. Castellano, Gary H. Lyman, Lisa Tachiki, Sumit A. Shah, Michael J. Glover, Daniel B. Flora, Elizabeth Wulff-Burchfield, Anup Kasi, Saqib H. Abbasi, Dimitrios Farmakiotis, Kendra Viera, Elizabeth J. Klein, Lisa B. Weissman, Chinmay Jani, Matthew Puc, Catherine C. Fahey, Daniel Y. Reuben, Sanjay Mishra, Alicia Beeghly-Fadiel, Benjamin French, Jeremy L. Warner
Summary: This study examined the impact of melanoma therapies on COVID-19 severity and organ dysfunction. The results showed that melanoma therapies did not increase the severity of COVID-19 or worsen organ dysfunction. Additionally, patients with a history of melanoma had similar 90-day survival compared with other cancer survivors after COVID-19.
Article
Oncology
Alonso La Rosa, Kathryn E. Mittauer, Amy E. Rzepczynski, Michael D. Chuong, Tugce Kutuk, Nema Bassiri, Nicole C. McAllister, Matthew D. Hall, James McCulloch, Diane Alvarez, Roberto Herrera, Alonso N. Gutierrez, Ranjini Tolakanahalli, Yazmin Odia, Manmeet S. Ahluwalia, Minesh P. Mehta, Rupesh Kotecha
Summary: For patients with newly diagnosed glioblastoma, the standard-of-care includes surgical resection, chemoradiotherapy, and adjuvant temozolomide. MR-guided radiotherapy using the ViewRay MRIdian A3i system allows for dedicated brain tumor treatment with daily MR imaging. We present a case of a glioblastoma treated using this workflow, demonstrating the potential for margin reduction and early disease progression detection.
News Item
Clinical Neurology
Eric J. Lehrer, Jason P. Sheehan, Daniel M. Trifiletti, Manmeet S. Ahluwalia
WORLD NEUROSURGERY
(2023)
Review
Oncology
Ahmad Ozair, Vivek Bhat, Reid S. Alisch, Atulya A. Khosla, Rupesh R. Kotecha, Yazmin Odia, Michael W. McDermott, Manmeet S. Ahluwalia
Summary: Brain tumors, particularly gliomas, are a diverse group of tumors, with low-grade gliomas being less invasive and having better survival rates compared to high-grade gliomas. This state-of-the-art review summarizes the current understanding of the role of epigenetics, specifically DNA methylation and histone modification, in the pathogenesis, clinical behavior, and outcomes of low-grade gliomas. The review also highlights potential therapeutic targets in associated cellular biomolecules, structures, and processes.
Article
Oncology
Vineeth Tatineni, Patrick J. O'Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
Summary: Radiotherapy, either through whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS), is the standard treatment for non-small cell lung cancer with brain metastases (NSCLCBM). Targeted therapies, such as EGFR-TKIs, have shown promise in NSCLCBM. This study compared the survival rates of standard radiotherapy modalities and a combination of radiotherapies and EGFR-TKIs, providing valuable information for future treatment plans.
Article
Oncology
Eric J. Lehrer, Atulya A. Khosla, Ahmad Ozair, Jason Gurewitz, Kenneth Bernstein, Douglas Kondziolka, Ajay Niranjan, Zhishuo Wei, L. Dade Lunsford, David Mathieu, Claire Trudel, Christopher P. Deibert, Timothy D. Malouff, Henry Ruiz-Garcia, Jennifer L. Peterson, Samir Patel, Phillip Bonney, Lindsay Hwang, Cheng Yu, Gabriel Zada, Piero Picozzi, Andrea Franzini, Luca Attuati, Rahul N. Prasad, Raju R. Raval, Joshua D. Palmer, Cheng-chia Lee, Huai-che Yang, Kareem R. Fakhoury, Chad G. Rusthoven, Daniel R. Dickstein, Jason P. Sheehan, Daniel M. Trifiletti, Manmeet S. Ahluwalia
Summary: This study found that the risk of radiation necrosis (RN) and symptomatic RN (SRN) increases with V12 Gy exceeding 10 cm3 in the treatment of non-small cell lung cancer (NSCLC) brain metastases using single fraction stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI). However, concurrent use of ICI and SRS does not appear to increase this risk.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Roy Strowd, Benjamin Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y. Wen, Manmeet Ahluwalia, Anna Piotrowski, Arati Desai, Jennifer L. Clarke, Frank S. Lieberman, Serena Desideri, L. Burt Nabors, Xiaobu Ye, Stuart Grossman
Summary: PT2385 monotherapy showed limited activity in patients with first recurrent GBM. However, signals of activity were observed in GBM patients with high systemic exposure and acidic lesions on CEST imaging. A second-generation HIF2 alpha inhibitor is currently being studied.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Juyeun Lee, Michael Nicosia, Ellen S. Hong, Daniel J. Silver, Cathy Li, Defne Bayik, Dionysios C. Watson, Adam Lauko, Kristen E. Kay, Sabrina Z. Wang, Sadie Johnson, Mary McGraw, Matthew M. Grabowski, Danielle D. Kish, Amar B. Desai, Wendy A. Goodman, Scott J. Cameron, Hideho Okada, Anna Valujskikh, Robert L. Fairchild, Manmeet S. Ahluwalia, Justin D. Lathia
Summary: This study demonstrates the crucial role of T cells in driving sex differences in glioblastoma (GBM) progression. Male mice exhibited accelerated tumor growth with decreased frequency and increased exhaustion of CD8+ T cells in the tumor. Furthermore, a higher frequency of progenitor exhausted T cells was found in males, with improved responsiveness to anti-PD-1 treatment. These findings highlight the importance of sex-biased predetermined behavior of T cells in GBM.
Article
Clinical Neurology
Eric J. Lehrer, Manmeet S. Ahluwalia, Jason Gurewitz, Kenneth Bernstein, Douglas Kondziolka, Ajay Niranjan, Zhishuo Wei, L. Dade Lunsford, Kareem R. Fakhoury, Chad G. Rusthoven, David Mathieu, Claire Trudel, Timothy D. Malouff, Henry Ruiz-Garcia, Phillip Bonney, Lindsay Hwang, Cheng Yu, Gabriel Zada, Samir Patel, Christopher P. Deibert, Piero Picozzi, Andrea Franzini, Luca Attuati, Rahul N. Prasad, Raju R. Raval, Joshua D. Palmer, Cheng-Chia Lee, Huai-Che Yang, Brianna M. Jones, Sheryl Green, Jason P. Sheehan, Daniel M. Trifiletti
Summary: This retrospective multicenter study investigated the predictors of treatment-related imaging changes (TRICs) and their impact on patient survival in the management of brain metastases using immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS). The results showed that TRICs were associated with improved overall survival, indicating that the presence of TRICs may increase the survival time of patients after treatment with ICIs and SRS.
JOURNAL OF NEUROSURGERY
(2023)
Article
Medicine, Research & Experimental
Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary, Herbert Newton, Ahmad Ozair, Atulya A. Khosla, Andrew B. Nixon, Bonne J. Adams, Ben K. Seon, David M. Peereboom, Charles P. Theuer
Summary: In this study, TRC105 showed limited activity as monotherapy for bevacizumab-refractory GBM, but combination therapy with bevacizumab resulted in a meaningful median survival. Further clinical trials are needed to evaluate the efficacy of this combination therapy in GBM patients.
COMMUNICATIONS MEDICINE
(2023)